Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGM-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 13 Nov 2023 Results developing and validating a mathematical model of HFrEF and GDMT treatment based on EMPHASIS-HF, PARADIGM-HF and DAPA-HF, presented at the American Heart Association Scientific Sessions 2023
- 13 Nov 2023 Results of PARAGON-HF and PARADIGM-HF assessing sacubitril/valsartan versus valsartan or enalapril in patients with HF, presented at the American Heart Association Scientific Sessions 2023